116 related articles for article (PubMed ID: 36534630)
1. Molecular markers of neuro-oncogenesis in patients with glioblastoma.
Kopylov AM; Antipova OA; Pavlova GV
Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(6):99-105. PubMed ID: 36534630
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
3. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.
Bao S; Wu Q; McLendon RE; Hao Y; Shi Q; Hjelmeland AB; Dewhirst MW; Bigner DD; Rich JN
Nature; 2006 Dec; 444(7120):756-60. PubMed ID: 17051156
[TBL] [Abstract][Full Text] [Related]
4. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
5. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
6. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
7. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
Di K; Linskey ME; Bota DA
Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
[TBL] [Abstract][Full Text] [Related]
8. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
9. Presence of pluripotent CD133+ cells correlates with malignancy of gliomas.
Thon N; Damianoff K; Hegermann J; Grau S; Krebs B; Schnell O; Tonn JC; Goldbrunner R
Mol Cell Neurosci; 2010 Jan; 43(1):51-9. PubMed ID: 18761091
[TBL] [Abstract][Full Text] [Related]
10. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
11. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.
Wang J; Sakariassen PØ; Tsinkalovsky O; Immervoll H; Bøe SO; Svendsen A; Prestegarden L; Røsland G; Thorsen F; Stuhr L; Molven A; Bjerkvig R; Enger PØ
Int J Cancer; 2008 Feb; 122(4):761-8. PubMed ID: 17955491
[TBL] [Abstract][Full Text] [Related]
12. CD163, a novel therapeutic target, regulates the proliferation and stemness of glioma cells via casein kinase 2.
Chen T; Chen J; Zhu Y; Li Y; Wang Y; Chen H; Wang J; Li X; Liu Y; Li B; Sun X; Ke Y
Oncogene; 2019 Feb; 38(8):1183-1199. PubMed ID: 30258108
[TBL] [Abstract][Full Text] [Related]
13. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
14. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.
Liu G; Yuan X; Zeng Z; Tunici P; Ng H; Abdulkadir IR; Lu L; Irvin D; Black KL; Yu JS
Mol Cancer; 2006 Dec; 5():67. PubMed ID: 17140455
[TBL] [Abstract][Full Text] [Related]
15. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
[TBL] [Abstract][Full Text] [Related]
17. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
[TBL] [Abstract][Full Text] [Related]
18. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma.
Rebetz J; Tian D; Persson A; Widegren B; Salford LG; Englund E; Gisselsson D; Fan X
PLoS One; 2008 Apr; 3(4):e1936. PubMed ID: 18398462
[TBL] [Abstract][Full Text] [Related]
19. CD133 and BMI1 expressions and its prognostic role in primary glioblastoma.
Sibin MK; Lavanya CH; Bhat DI; Rao N; Geethashree N; Vibhuti W; Chetan GK
J Genet; 2015 Dec; 94(4):689-96. PubMed ID: 26690524
[TBL] [Abstract][Full Text] [Related]
20. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
